Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9113781 | 0.92 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL18375234 | 0.89 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL11254327 | 0.89 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL18875928 | 0.88 | MMP2 (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL17337848 | 0.88 | ALPI (0.54) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL16559587 | 0.88 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL2927527 | 0.88 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL17225991 | 0.87 | OPRD1 (0.47) | HDAC8 | |
| SCHEMBL3409209 | 0.87 | REN (0.60) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL27163859 | 0.87 | REN (0.60) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662999-B2 | Recognition of oligosaccharide molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases | NATIONAL INSTITUTES OF HEALTH (NIH) (US) | 2010-02-16 | — | — | US | disclosed |
| US-20070232674-A1 | RECOGNITION OF OLIGIOSACCARIDE MOLECULAR TARGETS BY POLYCATIONIC SMALL MOLECULE INHIBITORS AND TREATMENT OF IMMUNOLOGICAL DISORDERS AND INFECTIOUS DISEASES | MEDIQUEST THERAPEUTICS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070093424-A1 | RECOGNITION OF OLIGIOSACCARIDE MOLECULAR TARGETS BY POLYCATIONIC SMALL MOLECULE INHIBITORS AND TREATMENT OF IMMUNOLOGICAL DISORDERS AND INFECTIOUS DISEASES | MEDIQUEST THERAPEUTICS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-7199267-B1 | Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases | MEDIQUEST THERAPEUTICS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232674-A1 | RECOGNITION OF OLIGIOSACCARIDE MOLECULAR TARGETS BY POLYCATIONIC SMALL MOLECULE INHIBITORS AND TREATMENT OF IMMUNOLOGICAL DISORDERS AND INFECTIOUS DISEASES | CD14, CD74, OSTC | ALPI 3568/4885PKM 3684/4885PTGS1 291/4885 |
| US-20070093424-A1 | RECOGNITION OF OLIGIOSACCARIDE MOLECULAR TARGETS BY POLYCATIONIC SMALL MOLECULE INHIBITORS AND TREATMENT OF IMMUNOLOGICAL DISORDERS AND INFECTIOUS DISEASES | CD14, CD74, OSTC | ALPI 3568/4885PKM 3684/4885PTGS1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.